DDB CV 2 of 29

Stanford University Palo Alto, California UNIVERSITY AND HOSPITAL STAFF APPOINTMENTS 1990 - 1991 Clinical Instructor Department of Internal Medicine University of California, San Diego Medical Center San Diego, California 1994 - 2000 Assistant Clinical Professor of Medicine Division of Cardiology

University of California, San Diego 1994 - Present Associate Director, Advanced Heart Failure Treatment Program

University of California, San Diego UCSD Medical Center, San Diego, California 2000 - 6/2006 Associate Clinical Professor of Medicine Division of Cardiology University of California, San Diego 7/2006 - Present Clinical Professor of Medicine Division of Cardiology University of California, San Diego 2004 - Present Director, Women’s Cardiovascular Health Program Division of Cardiology University of California, San Diego 2006 - Present Acting Medical Director, Cardiac Transplantation Program University of California, San Diego 2006 - Present Professor of Medicine, Part Time Faculty, Supervisory Attending

Cardiology Fellow Continuity Clinic La Jolla VA Medical Center LICENSURE California Medical License G065241 DEA Registration No: BH1812153 Fluoroscopy Permit No: RHC 137933 CERTIFICATIONS 1990 - 2000 American Board of Internal Medicine 1996 - 2010 Cardiovascular Disease/ ABIM Specialty Board 1997 Fellow, American College of Cardiology (FACC) 1997 Radiology/Fluoroscopy Certificate

DDB CV 3 of 29

2000 Fellow, Society of Geriatric Cardiology HONORS AND AWARDS 1984 NIH Student Research Grant 1985 Lange Publications Class Contribution Award 1986 -1987 American Association of University Women, Selected Professions

Fellowship 1987 A. Baird Hastings Society 1999 - 2000 Selected Fellowship, National Center for Leadership in Academic

Medicine, peer selected Class Valedictorian 2000 - 2001 American Hospital Association Cardiovascular Health Fellowship 2001 - 2005 Elected District Councilor, District X, California Chapter, ACC 2002 - 2004 Medical Director, Women’s Legacy Luncheon Program, AHA 2002 “Best Doctors in America” (Cardiology)- Published in San Diego Magazine 2003 “Best Doctor in America” (Cardiology)- Published in San Diego Magazine 2003 Nominated by the American Biographical Institute for Honoring America’s

Distinguished Women to be published in the 10th Commemorative Edition of 2,000 Notable American Women

2004 “Best Doctor in America” (Cardiology)- Published in San Diego Magazine 2004 Honoree of Hadassah, San Diego for contribution to “Healthy Women,

`Healthy Lives” Program 2004 - 2005 Medical Director, Go Red for Women AHA Luncheon Program 2005 “Best Doctors” in America (Cardiology) – published in San Diego 2007 -2008 “Consumers Research Council Guide to America’s Top Cardiologists” 2009 “Best Doctors in America (Cardiology) 2011 Nominated by the Heart Failure Society of America as a “Technical Panel

Member for the Appropriate Use Criteria for Diagnostic Catheterization, The American College of Cardiology Foundation (ACCF)

PROFESSIONAL SOCIETIES (Active Membership)

American Heart Association (AHA) Fellow, American College of Cardiology (ACC) International Society for Heart and Lung Transplantation (ISHLT) Heart Failure Society of America (HFSA) Scientific Advisory Board, International Society of Heart Failure, Inc (ISHF) Fellow, Society of Geriatric Cardiology American College of Physicians (ACP)

UCSD COMMITTEE PARTICIPATION 2004 - Present Co-Chair, UCSD Heart Failure Quality Improvement Committee 1995 - 2001 UCSD Clinical Research Center Advisory Committee (IRB Equivalent) 1994 - Present Cardiothoracic Transplantation Committee 1999 - 2004 ICU Users Group 1999 - 2004 Cath Lab Users Group

DDB CV 4 of 29

1999 - 2004 UCSD Health Care Network Quality Improvement Committee 1994 - Present UCSD Division of Cardiology Quality Improvement Committee 1998 - 2000 Chair, Division of Cardiology Quality Improvement Committee 1994 - Present UCSD Department of Medicine Interviewer, Intern Applicants Selection

Committee 1995 - Present UCSD Division of Cardiology Fellowship Applicant Selection Committee 1998 - 2000 Cardiology Representative, DOM Quality Improvement Committee 1999 - 2001 UCSD Home Care Professional Advisory Council 2002 - 2004 UCSD SOM Academic Advisory Medical Student Counselor 2006 - Present UCSD DOM Faculty Recruitment Committee 2006 - Present UCSD Abdominal Organ Transplant Committee Cardiovascular Advisor 2006 - Present UCSD Medical Center Heart Failure Core Measures Team 2008 - 2009 Palliative Care Committee, Ad-Hoc Team 1

NATIONAL COMMITTEE AFFILIATION / MEMBERSHIP Associate, American Heart Association (AHA)

­ Council on Clinical Cardiology Fellow, American College of Cardiology (ACC)

­ ACC/AHA Joint Committee on Heart Failure & Transplantation Heart Failure Society of America (HFSA)

­ Guidelines and Clinical Positions Committee (1999-2004) ­ Guidelines and Clinical Positions Committee, Ad Hoc Member (2004-2006) ­ National HF Awareness Committee (2000-2008) ­ Education Committee (2007-present) ­ HFSA Representative to ACC/AHA Women in Cardiology Summit 2001

International Society for Heart and Lung Transplantation (ISHLT) ­ Council on Heart Failure & Transplantation Medicine

Advisory Council to Improve Outcomes Nationwide-Heart Failure (ACTION HF) ­ On-Site Insights Subcommittee Member (1999-2001)

Data Safety Monitoring Board for PREDICT – Prospective Evaluation and Identification of Cardiac Decompensation in Patients with Heart Failure Bioimpedance Cardiograph Test (2001-3)

“Think Tank” Women and Cardiovascular Disease 2005-present. National expert panel to aid the NIH/FDA/NHLBI in identifying and prioritizing key issues regarding gender and CVD for funding opportunities/RFA development.

SCIENTIFIC SESSIONS ABSTRACT REVIEWER

1994-Present American College of Cardiology 1994-Present Heart Failure Society of America 1994-Present International Society of Heart Failure

JOURNAL OR PUBLICATION REFEREE

Circulation, Guest Reviewer of Guideline for the Evaluation and Management of Chronic Heart Failure in the Adult, 2004. Congestive Heart Failure Journal of Heart and Lung Transplantation

DDB CV 5 of 29

American Journal of Medicine American Heart Journal Journal of Cardiovascular Nursing

EDITORIAL BOARD MEMBER

2000-Present Journal of the American College Cardiology, Editorial Board 2000-present Journal of Cardiac Failure, Editorial Board 2003-present Journal of the American College of Cardiology 2005-present Journal of Heart and Lung Transplantation 2009-present Congestive Heart Failure

INVITED EDITORSHIPS Co-Editor for Special Edition, Journal of Cardiac Failure – (2001)

Editor, Congestive Heart Failure “Neurhormonal Blockade in the Treatment of Heart Failure: Where Do We Go From Here?” 8:25 245-280, September/October 2002

Editor, Textbook. Management of Heart Failure, John Wiley & Sons, Ltd, 1st Edition

Published 2010 SPEAKERS BUREAUS (Active, 2008)

­ Glaxo Smith Kline ­ Novartis ­ Medical Education Speakers Network ­

STORY CONSULTANT, INTERVIEWEE or OTHER ADVISORY POSITION

­ ABC News ­ California Seniors Magazine ­ Union Tribune, San Diego ­ KUSI News, San Diego Channel 10 ­ KFMB News, San Diego Channel 8 ­ ACC Web MD ­ American Board of Internal Medicine, Cardiovascular Board Questions (Invited

Submission) ­ Advisory Panel, Medi-Cal, Heart & Heart-Lung Transplantation Center Standards ­ San Diego Magazine

Advisory Boards ­ Coreg Regional Advisory Board - (2000-present)

Advisory Panel, Medi-Cal, Heart & Heart-Lung Transplantation Center Standards - (2000-present)

DDB CV 6 of 29

Scientific Advisory Board, International Society of Heart Failure, Inc (ISHF) - (2000-present) Regional Advisory Board, SmithKline-Beecham Pharmaceuticals - (2000-present) Scientific Advisory Board, Pulse Metric, Inc. - (2000-present) Scientific Advisor, Res Med, Inc. - (2000-present) Scientific Advisor, BioSite Diagnostics Inc. - (2000-present) Scientific Advisor, Pfizer, Inc. - (2000-present) Scientific Advisor, Sanofi Pharmaceuticals - (2000-present) Scientific Advisor, Novartis Pharmaceuticals - (2000-present)

UNIVERSITY & PUBLIC SERVICE ACTIVITIES

Preceptor, GlaxoSmithKline Representatives Training Program Preceptor, Medtronic Representatives Training Program Preceptor, Amgen Representatives Training Program Preceptor, Pfizer Representatives Training Program Director, San Diego Heart Failure Awareness Foundation Director, Women’s Cardiovascular Disease Awareness Foundation UCSD SOM Medical Student Faculty Advisor (10 students) Treasurer Heart Failure Foundation Medical Director, San Diego Affiliate, AHA Women’s Legacy & Go Red for Women Campaigns 2002-2006 UCSD National Center of Leadership in Academic Medicine, Faculty Mentor 2007-present Voluntary Faculty Speaker Sulpizio Family Cardiovascular Center Heart Fair 1/20/2007 Voluntary Faculty Speaker Sulpizio Family Cardiovascular Center Heart Fair 1/19/2008 Volunteer Faculty, UCSD undergraduate MSTP/SURF program July 2008 Volunteer Faculty Mentor, SOM Medical Students 2010

TRAINEES SUPERVISED

1997-1998 Johannes Kuiper, M.D. - Fellow in Cardiology 1998-1999 Tina Reyes - Independent Study Project (ISP) for UCSD School of

Medicine 1998 - 2000 Gilanthony Ungab, M.D. – Cardiology Fellowship 2001 Vijaya Shree Chintala, M.D. – Postdoctoral Research Fellow 2002 - 2004 Alex Adler, MD – Cardiology Heart Failure Fellow 2002 - 2004 Ottar Lunde, MD – Cardiology Heart Failure Fellow

2004 - 2005 Robert Hannah, M.D. –Visiting Medical Student, Faculty Mentor for Independent Study Project (Albert Einstein School of Medicine)

2005 - 2006 Dawn Lombardo, DO – Cardiology Heart Failure Fellow 2010-2011 Payman Zamani, M.D. – Cardiology Heart Failure Fellow 2011-2012 Khwaja Sami Alim, M.D. – Cardiology Heart Failure Fellow

UCSD CONTRACT & GRANT SUPPORT

DDB CV 7 of 29

1995 -1996 Boerhinger Pharmaceuticals – (TOR MF 8382) Effect of Edema on the Absorption of Demadex and Lasix in Patients with Decompensated Congestive Heart Failure – Principal Investigator

1995 -1998 General Clinical Research Center Clinical Associate Physician (CAP) NIH:

Plasma Ultrafiltration as an alternative to Inotropic therapy for moderate to severe congestive heart failure. – Principal Investigator.

1995 - 1999 NHLBI - BEST (Grant #VA965077) Beta-Blocker Evaluation of Survival Trial: To assess the effects of beta-blocker therapy on the clinical course of patients with NYHA Class III-IV Heart Failure. – Co-Investigator.

1996 - 1999 NHLBI - BEST (Grant #VA965077) Beta-Blocker Evaluation of Survival

Trial: Echo Sub-Study - To evaluate changes in cardiac structure and function during beta-blocker therapy. – Co-Investigator.

1997 -1998 Academic Senate - Supervision of Pulmonary fellow Joseph Resnikoff,

M.D.: Characterization of Sleep Disordered Breathing in Cardiomyopathy. – Principal Investigator.

1997 - 1999 Pfizer: PRAISE-2 (035-185-04B) Prospective Randomized Amlodipine

Survival Evaluation-2: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of amlodipine in survival in patients with congestive heart failure. – Co-Investigator.

1997 -1999 Merck: ELITE II Multicenter double-blind randomized, parallel, captopril-

controlled study to evaluate the effects of losartan on mortality in patients with symptomatic heart failure. – Co-Investigator.

1997 -1999 Bristol-Myers Squibb: IMPRESS – Inhibition of MetalloProtease by BMS-

186716. – Co-Investigator. 1998 -1999 Parke-Davis Pharmaceutical Research: A 12 week, Double-Blind, Placebo-

Controlled, Multicenter Study of Oral YM087CCI-1025. – Co-Investigator. 1998 - 2000 Guidant/CPI: VIGOR CHF Effect of biventricular pacing for CHF. – Co-

Investigator. 1998 - 2000 CPI: Evaluation of the Ventak CHF AICD with Biventricular pacing for

CHF. – Co-Investigator. 1998 - 2001 Wyeth Ayerst: VPA Study - A randomized double-blind multicenter

comparison of the safety and effects of VPA-985 and placebo in the treatment of patients with hyponatremia. – Co-Investigator.

1998 - 2001 Eli Lilly/Covance: Moxcon - The effect of sustained-release moxonidine on

mortality & morbidity in patients with congestive heart failure. – Co-Investigator.

DDB CV 8 of 29

1998 - 2001 SmithKline Beecham: COPERNICUS - To evaluate effects of carvedilol on survival in patients with NYHA Class IIIb-IV Heart Failure Symptoms. – Co-Investigator.

1999 - 2000 Parke-Davis: A Randomized, Double-Blind, Multicenter, Placebo-

Controlled Study of the IV Dose Response of YM087 (CI-1025) on Cardiopulmonary Hemodynamics in Patients with Class III/IV Heart Failure. – Co-Investigator.

1999 - 2001 Actelion, Ltd.: RITZ-1 (9AC-051-3) Evaluation of Tezosentan in Heart

Failure patients.– Principal Investigator. 1999 - 2001 Actelion, Ltd.: RITZ-2 (AC-051-302) HESPARION - Evaluation of

Tezosentan in Heart Failure patients. – Principal Investigator.

1999 - 2002 Immunex: RENAISSANCE To assess effects of soluble TNF receptor in heart failure patients. – Co-Investigator.

1999 - 2002 AstraZeneca: CHARM Candesartan Cilexitil in Heart Failure Assessment of

Reduction in Mortality and Morbidity. – Co-Investigator. 2001 - 2003 Pulse Metric: Dynapulse - Non-Invasive Blood Pressure Waveform

Analysis to Evaluate the Variability and Reproducibility of Cardiac Output, Systemic Vascular Resistance and dp/dT (BP) Heart Failure Patients. – Principal Investigator.

2001 - 2003 CardioDynamics: PREDICT - Prospective Evaluation and Identification of

Cardiac Decompensation in Patients with Heart Failure Bioimpedance Cardiograph Test –Invited Chairperson, Data Safety and Monitoring Committee.

2001 - 2003 CV Therapeutics: RANOLIZINE A phase II double-blind, parallel

pharmacokentic and safety study of Ranolizine administered alone and in combination with Digoxin once a day in patients with congestive heart failure. – Co-Investigator.

2001 - 2003 AstraZeneca Pharmaceuticals: REVERT A multicenter, double-blind,

placebo-controlled, randomized trial to evaluate the effects of extended release Metroprolol Succinate (Troprol XL) on cardiac remodeling in asymptomatic heart failure patients (NYHA Class I) with LV dysfunction. – Co-Investigator.

2001 - 2003 Biogen, Inc: (C-1701) A Randomized, Double-Blinded, Placebo-Controlled,

Dose Escalation Study of multiple oral dose administration of BG9928 in Stable Heart Failure Patients Protocol. – Co-Investigator.

2001 - 2004 Myogen, Inc: ESSENTIAL (MY-021) A Phase III, Randomized, Double-

Blind, Multicenter, Parrallell Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects. – Co-Investigator.

DDB CV 9 of 29

2002 - 2003 Amgen, Inc: STAMINA-HeFT Protocol Darbepoetin Alfa 20010170: A

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects with Symptomatic CHF and Anemia. – Principal Investigator.

2002 - 2003 Otsuka Maryland Research Institute: A Multi-center, Randomized, Double-

Blind, Parallel Group Study to Compare the Effects of 30 mg q.d. Versus 15 mg bId. Oral Administration of Tolvaptan (OPC-41061) in Patients with Congestive Heart Failure. – Co-Investigator

2002 - 2003 Takeda Pharmaceuticals: A Phase II, Double-Blind, Randomized,

Exploratory, Placebo Controlled Study of the Efficacy, Safety and Tolerability of MCC-135 Comparing QD vs BID Doses in Subjects with Congestive Heart Failure, NYHA Class II/III. – Co-Investigator

2002 - 2004 Orion Pharma Corp: REVIVE Randomized, Mutlicenter Evaluation of

Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure. – Principal Investigator.

2002 - 2005 Bristol-Myers Squibb: Irbesartan in Heart Failure with Preserved Systolic

Function (I-PRESERVE). – Co-Investigator. 2003 - 2003 Vasogen: AMulti-Center, Randomized, Double-Blind, Paralledl Group,

Placebo-Controlled Study to assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with chronic heart Failure. – Principle

2003 - 2004 Actelion, Ltd.: VERITAS-1. AC-051-306: A Multicenter, Double-blind,

Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients with Acute Heart Failure. – Principal Investigator

2003 - 2004 Amgen: Amgen Feasibility Study. – Principal Investigator 2003 - 2005 Biosite: (RABBIT) Rapid Assessment of Bedside BNP in Treatment of

Heart Failure. – Co-Investigator. 2003 - 2007 NIH Grant and Duke Clinical Research Institute: HF-ACTION: Heart

Failure and A Controlled Trial Investigating Outcomes of Exercise Training. – Principal Investigator.

2004 - 2005 Pfizer, Inc.: A Randomized, Double-blind, Multicenter Study Evaluating

the effects of Eplerenone vs. Placebo on Ventricular Systolic Dysfunction (EF<35%) and Mild to Moderate Heart Failure. – Principal Investigator

2004 - 2005 NovaCardia, Inc. : (CK-201) A randomized, double-blind, placebo

controlled study dose-ranging study of the effects of KW-3902, both as

DDB CV 10 of 29

monotherapy and in combination with furosemide, on diuresis and renal function in patients with congestive heart failure (CHF) and renal impairment. – Co-Investigator.

2004 - 2006 Vasogen, Inc.: ACCLAIM: A Multicenter, Double-blind, Parallel Group,

Placebo-controlled Study to Assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure Protocol No. 0202. – Principal Investigator.

2004 - 2006 Fujisawa Healthcare Inc.: A Phase 2, Dose Escalation Evaluation of the

Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects with Congestive Heart Failure. – Co-Investigator.

2004 - 2007 Orqis Medical: MOMENTUM - A Multicenter Trial of the Orqis Medical CRS

for the Enhanced Treatment of CHF Unresponsive to Medical Therapy. – Co-Investigator.

2005 - 2006 GlaxoSmithKline: An open, nonrandomized comparison of

pharmacokinetic profiles of carvedilol (SK&F-105517) MR and IR on repeat dosing in chronic CHF patients and survivors of an acute MI and LVD. – Co-Investigator.

2005 - 2006 Novartis Pharmaceuticals: A twelve-week, randomized, double-blind,

multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients with stable heart failure. – Co-Investigator.

2005 - 2006 Titan Pharmaceuticals: A Multi-Center, Randomized, Double-Blind,

Placebo-Controlled Study of DITPA in Patients with NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels. – Co-Investigator.

2006 - 2007 Zealand Pharma: A Phase II, Multi-Center, Randomized, Double-Blind,

Flexible Dose Study of ZP120 Administered as I.V. Infusion as Add-On Therapy in Patients with Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated with Furosemide – Co-Investigator.

2006 - 2007 PhiloMetron, Inc.: (422206_02) Heart Failure Hydration Monitoring

System. Fluid Increase Pilot Study. – Principal Investigator. 2006 - 2007 NovaCardia, Inc.: PROTECT (CKI-301) A Randomized, Double-Blind,

Placebo-Controlled Study of the Effects of KW-3902IV in Maintaining Renal Function and Improving the Clinical Outcome of Patients with Congestive Heart Failure and Renal Impairment Who Require Hospital Treatment with Intravenous Loop Diuretics for Fluid Overload. – Co-Investigator.

DDB CV 11 of 29

2006 - 2007 PDL BioPharma: (Ularitide 1503) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure. – Co-Investigator

2006 - 2008 Encysive Pharmaceuticals: A Phase 2 Randomized, Double-Blind, Placebo-

Controlled Exploratory Efficacy Study of Sitaxsentan Sodium to Improve Impaired Tolerance in Subjects with Diastolic Heart Failure. – Co-Investigator.

2006 - Present Amgen: RED-HF (20050222) A Double-blind, Randomized, Placebo-

controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia. – Principal Investigator.

2006 - 2010 CardioDynamics: PREVENT HF (06001-M2-124-1-3) Prevention of Heart

Failure Events with Impedance Cardiography Testing. – Co-Investigator. 2006 - Present Celladon, Inc.: (CELL 002) Assessment of Antibodies to Adeno-Associated

Vector Type 1 in Patients with Heart Failure. – Co-Investigator. 2007 - Present NovaCardia, Inc.: PROTECT (CKI-302) A multicenter, randomized, double-

blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy. – Co-Investigator.

2007 - 2009 Novacardia, Inc.: REACH UP (CKI-303) A multicenter, randomized,

double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in subjects hospitalized with worsening renal function and heart failure requiring intravenous therapy. – Co-Investigator.

2007 - 2009 Bayer Healthcare, Inc.: (BAY 59-7939/12980) A Randomized, Multicenter

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Rivaroxaban in Subjects with Acute (Open-Label, Active-Controlled) or Chronic (Double-Blind, Placebo-Controlled) Congestive Heart Failure. – Co-Investigator.

2007 - 2009 Bayer Healthcare, Inc.: (BAY 58-2667) Placebo-controlled, randomized,

double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with decompensated chronic congestive heart failure. – Co-Investigator.

2007 - 2010 Scios, Inc.: ASCEND HF (A 093) Double-Blind, Placebo-Controlled,

Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. – Co-Investigator.

DDB CV 12 of 29

2007- 2010 Cardiokine: BALANCE (CXL-LX-3401) Lixivaptan versus Placebo in the

Treatment of Hyponatremia: A Randomized, Double Blind Trial in Patients with Heart Failure and Volume Overload. – Principal Investigator

2007 - 2010 Corventis, Inc.: MUSIC Multi-sensor Monitoring in Congestive Heart

Failure Patients. – Co-Investigator. 2007 -2010 Celladon, Inc.: CUPID Trial (CELL 001) Calcium Up-Regulation by

Percutaneous Administration of Gene therapy In Cardiac Disease. A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Dose Escalation Trial of Intracoronary Administration of MYDICAR™ (AAV1/SERCA2a) in Subjects with Heart Failure. – Co-Investigator.

2008 - Present Cytokinetics: (CY 1121) A Phase II, Multi-Center, Double-Blind,

Randomized, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 in Patients with Stable Heart Failure. – Co-Investigator.

2008 - Present Biosite: (Clinical Protocol BSTE-0405) NGAL Evaluation Along with B-Type

Natriuretic Peptide in Acutely Decompensated HF. (GALLANT). – Co-Investigator.

2008-2010 Biogen Idec: TRIDENT (160-HF-301) A Randomized, Double-Blind,

Placebo-Controlled, Parallel-Group, Study to Assess the Effects of Intravenous BG9928 on body Weight in Subjects with Acute Decompensated Heart Failure and Rental Insufficiency – Co-Investigator.

2009-Present Biosite: HABIT (BSTE-0108) Assessment with BNP in the Home –

Principal Investigator 2009-2011 Corthera, Inc: RELAX-AHF (RLX.CHF.003) a Phase II/III, Multicenter,

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects with Acute Heart Failure. – Co-Investigator.

2010-Present Novartis: PARADIGM A Multicenter, Randomized, Double-blind, Parallel

Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients with Mchronic Heart Failure and Reduced Ejection Fraction

2011-Present Gilead Sciences Inc. RANOLAZINE: The Effects of Ranolazine on Exercise

Capacity in Patients with Heart Failure with Preserved Ejection Fraction.

2011-Present Amgen: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

DDB CV 13 of 29

BIBLIOGRAPHY A. PUBLISHED MANUSCRIPTS

1. Rozanski A, Diamond GA, Berman D, Forrester JS, Morris D. Swan HJC., “The Declining Specificity of Exercise Radionuclide Ventriculography”, N Engl J Med 309 (9):518-22, 1983.

2. Morris D, Rozanski A, Berman DS, Diamond GA, Swan HJC. “Non-Invasive

Prediction of The Angiographic Extent of Coronary Artery Disease after Myocardial Infarction: Comparison of Clinical, Bicycle Exercise Electrocardiographic and Ventriculographic Parameters”, Circulation 70(2):192-201, 1984.

3. Rozanski A, Diamond GA, Forrester JS, Berman DS, Morris D. Swan HJC.

“Alternative Referent Stands for Cardiac Normality”, Ann Int Med 101 (2):164-171, 1984.

4. Rozanski A, Diamond GA, Jones R, Forrester JS, Berman DS, Morris D, Pollock BH,

Freeman M, Swan HJC. “A Format for Integrating the Interpretation of Exercise Ejection Fraction and Wall Motion and Its Application in Identifying Equivocal Responses”, J Am Coll Cardiol 5(2):238-248, 1985.

5. Rozanski A, Diamond GA, Forrester JS, Berman DS, Morris D, Jones RH, Okada R,

Freeman M, Swan HJC. “Should the Intent of Testing Influence Its Interpretation?” J Am Coll Cardiol 7(1):17-24, 1986.

6. Engler RL, Dahlgren MD, Morris D, Peterson M, Schmid-Schoenbein GW. “Role of

Leukocytes in the Response to Acute Myocardial Ischemia and Reflow in Dogs”, Am J Physiol 251:H314-399, 1986.

7. Diamond GA, Rozanski A, Forrester JS, Morris D, Pollock BH, Staniloff HM,

Berman DS, Swan HJC. “A Model for Assessing the Sensitivity and Specificity of Tests Subject to Selection Bias: Application to Exercise Radionuclide Ventriculography for the Diagnosis of Coronary Artery Disease”, J Chron Dis 39(5) 343-355, 1986.

8. Morris D, Mulvihill D, Lew W. “Risk of Developing Complete Heart Block During

Bedside Pulmonary Artery Catheterization in Patients with Left Bundle Branch Block”, Arch Int Med 147:2005-2010, 1987.

9. Hermann DD and Greenberg BH. “Vasodilator Therapy in Left Heart Valvular

Regurgitation”, ACC Current J Review, Pp 27-29, Jan/Feb 1998. 10. Denise D. Hermann and Barry H. Greenberg. Pro/Con Article “Should All Patients

With Heart Failure and Systolic Ventricular Dysfunction Be Anticoagulated With Warfarin?” Mosby-Wolfe Publications & Med. Comm., J of Coronary Artery Disease: Debates & Reviews. July, Number 9:2-14, 1999.

DDB CV 14 of 29

11. Denise D. Hermann. “Naturoceutical Agents and Cardiovascular Medicine – The Hope, Hype and The Harm”, ACC Current J Review, Sept/Oct:53-57, 1999.

12. Heart Failure Society of America Committee Members and Executive Council: Heart

Failure Society of America (HFSA) Practice Guidelines: “HFSA Guidelines for the Management of Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction – Pharmacological Approaches”. CHF, Vol 6: No 1, January/February 2000.

13. Denise D. Hermann and Barry H. Greenberg. “America’s Silent and Lethal

Epidemic”, Opinion Editorial, San Diego Union-Tribune, Section E: B-7, February 15, 2000.

14. Greenberg BH, Hermann DD, Pranulis MF, Lazio L, Cloutier D. Reproducibility of

Impedance Cardiography Hemodynamic Measures in Clinically Stable Heart Failure Patients. Congestive Heart Failure, 6(2) 74-80, March/April 2000.

15. Hermann D and Kahn A. “Should physicians recommend Coenzyme Q-10

supplementation for patients with heart failure?” Harcourt Health Communications, J of Coronary Artery Disease: Debates & Reviews. 14:2-6, 2000

16. Sharma A, Hermann DD, Mehta RL. “Clinical benefit and approach of

ultrafiltration in acute heart failure.” Cardiology 96(3-4):144-154, 2001 17. Hermann DD. “Naturoceutical agents in the management of cardiovascular

disease” J Cardiovasc Drugs 2002: 2 (3): 173-196. 18. Greenberg, BH, Hermann, DD, Guest Editors. Neurohormonal Blockade in the

Treatment of Heart Failure: Where Do We Go From Here? Congestive Heart Failure 8:245, 2002.

19. Hermann DD. Beta-Adrenergic Blockade 2002: A pharmacologic Odyssey in

Chronic Heart Failure. Congestive Heart Failure 8:262 – 269, 2002. 20. Hoppe BL, Hermann DD. Sex Differences in the Causes and Natural History of

Heart Failure. Current Cardiology Reports 2003 May; 5(3):193-9. 21. Barnard DD. Heart Failure in Women. Current Cardiology Reports. Volume 7

Number 3 Pages 159-165, May 2005. 22. Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, Baughman KL,

Boehmer JP, Deedwania P, Dunbar SB, Elkayam U, Gheorghiade M, Howlett JG, Konstam MA, Kronenberg MW, Massie BM, Mehra MR, Miller AB, Moser DK, Patterson JH, Rodeheffer RJ, Sackner-Bernstein J, Silver MA, Starling RC, Stevenson LW, Wagoner LE. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Failure 2006; 12:e1–e122.

23. Keteylan SJ, Isaac D, Thadani U, Roy BA, Bensimhon DR, MKelvie R, Russell SD,

Hillkamp AS, Kraus WE, Barnard D included as HF-ACTION Investigators. Safety of Symptom-Limited Cardiopulmonary Exercise Testing in Patients with

DDB CV 15 of 29

Chronic heart Failure due to Severe left Ventricular Systolic Dysfunction. Am Heart J. 2009 Oct; 158(4 Suppl): S72-S77.

24. Flynn KE, Lin L, Ellis SJ, Russell SD, Spertus JA, Whellan DJ, Piña IL, Fine LJ,

Schulman KA, Weinfurt KP, Barnard D included as HF-ACTION Investigators. Relationships Between Patient-Reported Outcome Measures and Clinical Measures in Outpatents with heart Failure. Am Heart J. 2009 Oct: 158(4 Suppl): S64-S71.

25. Forman DE, Clare R, Kitzman DW, Ellis SJ, Fleg JL, Chiare T, Fletcher G, Kraus WE,

Barnard D, included as HF-ACTION Investigators. Relationship of Age and Exercise Performance in Patients with Heart Failure: The HF-ACTION Study. Am Heart J. 2009 Oct; 158(4 Suppl): S6-S15.

26. Atchley AE, Kitzman DW, Whellan DJ, Iskandrian AE, Ellis SJ, Pagnaelli RA, Kao A, Abdul-Nour K, O’Connor CM, Ewald G, Kraus WE, Borges-Neto S, Barnard D, included HF-ACTION Investigators. Myocardial Perfusion, Function, and Dyssynchrony in Heart Failure Patients: Baseline Results from the SPECT Imaging Ancillary Study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial. Am heart J. 2009 Oct; 158(4 Suppl); S53-S63.

27. Gardin JM, Leifer ES, Fleg JL, Whellan D, Kokkinos P, LeBlanc MH, Wolfel E,

Kitzman DW, for the HF-ACTION Investigators and Barnard D included HF-ACTION Investigators. Relationship of Doppler-Echocardiographic left Ventricular Diastolic Function to Exercise Performance in Systolic Heart Failure: The HF-ACTION Study. Am Heart J. 2009 Oct; 158(4 Suppl): S45-S52.

28. Horwich TB, leifer ES, Brawner CA, FitzGerald MB, Fonarow GC, and Barnard D

included in HF-ACTION Trial. Am heart J. 2009 Oct; 158(4 Suppl): S31-S36. 29. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG,

Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O’Connor CM, Weinfurt KP, and Barnard D as included in HF-ACTION Trial. Effects of Exercise Training on Health Status in Patients with Chronic Heart Failure: Findings From the HF-ACTION Randomized Controlled Trial. JAMA. 2009 April 8; 301(14): 1451-1459.

30. Russell SD, Saval MA, Robbins JL, Ellestad MH, Gottlieb SS, Handberg EM, Zhou Y,

Chandler B, Barnard D included in HF-ACTION Investigators. Am Heart J. 2009 Oct; 158(4 Suppl): S24-S30.

31. Bin Thani, K Kaushal K, Barnard D, Copeland J, Prasad A. Coarctation of the

Thoracic Aorta Masquerading as Bilateral aorto-iliac stenosis. June 2011 Japanese Coll of Card. Pub; Elsevier. Article in Press

B. BOOKS

DDB CV 16 of 29

1. Greenberg BH, Hermann D. Contemporary Diagnosis and Management of Congestive Heart Failure. (1st Edition), Handbooks in Health Care Co., Newtown, PA, 2002.

2. Greenberg BG, Barnard D. Contemporary Diagnosis and Management of

Congestive Heart Failure. (2nd Edition), Handbooks in Health Care Co., Newtown, PA, 2004.

3. Greenberg BG, Barnard D. Contemporary Diagnosis and Management of

Congestive Heart Failure. (3rd Edition). Handbooks in Health Care Co., Newtown, PA, 2005.

4. HFSA 2006 Comprehensive Heart Failure Practice Guideline. Heart Failure Society

of America. Heart Failure Society of American, St. Paul, MN. 5. Greenberg BH, Barnard DD, Amsterdam EA, Liebson P, Grundy SM.

Contemporary Cardiovascular Continuum. Handbooks in Health Care Co, Newtown, PA 2006.

C. BOOK CHAPTERS

1. Norcross WA and Hermann DD. “Heart Failure” In: Manual of Family Practice. Little Brown Publisher; RB Taylor, Editor. 67:286-291, 1997.

2. Hermann DD and Greenberg BH. “Prognostic Factors” In: Heart Failure:

Scientific Principles & Clinical Practice. Churchill Livingstone, Inc., Publisher; P Poole-Wilson, Wilson Colucci, B Massie, K Chatterjee and A Coats, Editors. 30:439-454, 1997.

3. Norcross WA and Hermann DD. “Heart Failure” In: Family Medicine, Principles &

Practice. Springer Publisher; RB Taylor, Editor; 5th Edition. 79:693-703, 1997.

4. Mehta RL and Hermann D. “Dialysis and Ultrafiltration” In: Cardiac Intensive Care. WB Saunders Co., Publisher; DL Brown, Editor. 59:735-741, 1998.

5. Hermann DD and Greenberg BH. “Refractory Heart Failure: Beyond Standard

Therapy” In: Heart Failure Management. Martin Dunitz Publisher; N Sharpe, Editor. 15:199-216, 2000.

6. Hermann DD. “Acute and Chronic Heart Failure” In: Educational Review Manual

in Cardiovascular Disease. Castle Connolly Graduate Medical Publishing, LLC; AN DeMaria, Editor. Text & CD-ROM, V:2001.

7. Norcross WA and Hermann DD. “Heart Failure” In: Manual of Family Practice.;RB

Taylor, Editor. 2nd ed. Lippincott Williams and Wilkins; Philadelphia: 2002 p. 256-62 (Previously indicated as Little Brown & Company, Publisher)

DDB CV 17 of 29

8. Norcross WA and Hermann DD. “Heart Failure” In: Family Medicine, Principles & Practice, 6th edition, Springer Publisher; RB Taylor, Editor 6th ed. New York: Springer; 2003. p. 672-83

9. Norcross WA and Hermann DD. “Heart Failure: In: Taylor’s Cardiovascular

Diseases. Springer Publisher, RB Taylor, Editor. New York Springer, 2004. p. 115-144

10. Hermann DD. Naturoceuticals and other complementary therapies in the

prevention of cardiovascular disease In: Preventive Cardiology: A Practical Approach. McGraw-Hill; Wong ND, Editor. 2nd Edition. 2005. p. 543-57 (Book Chapter)

11. Barnard DD. Heart Failure In: Taylor’s Manual of Family Medicine. Lippincott

Williams & Wilkins, Editor 3rd Edition. 2008. p 306-318 (Book Chapter) 12. Greenberg BH, Barnard DD, Narayan, S. Management of Heart Failure

Chichester: John Wiley & Sons, Ltd., 2010

D. SELECTED ABSTRACTS

1. Gradman M, Morris D, Amsterdam EA, Low R, Joye JA, Foerster J, Laslett L, DeMaria AN, Mason DT. “Exercise Testing Before Hospital Discharge After Acute Myocardial Infarction: Correlation With Coronary Angiography and Long Term Prognosis”, Clin Res 28:176A, 1980.

2. Amsterdam EA, Morris D, Kimchi A, Low RI, Laslett L, Joye J, Lee G, DeMaria AN,

Mason DT. “Early Post-Myocardial Infarction Exercise Testing: Relationship of Results to Extent of Coronary Artery Disease”, Clin Res 29:175A, 1981.

3. Amsterdam EA, Kimchi A, Morris D, Low R, Laslett LR, Lee G, DeMaria AN, Mason

DT. “Early Post-Myocardial Infarction Exercise Testing: Relationship of Results to Extent of Angiographically Demonstrable Coronary Artery Disease”, 2nd World Congress on Cardiac Rehabilitation, Israel, December 1981.

4. Levey M, Rozanski A, Valovis R, Ford D, Morris D, Pantaleo N, Maddahi J, Swan

HJC, Berman D. “Comparative Ability of Upright and Supine Bicycle Exercise Electrocardiography to Detect Coronary Artery Disease”, Am J Cardiol 49(4):945, 1982

5. Rozanski A, Gutman J, Morris D, Levy R, Maddahi J, Waxman A, Berman D.

“Assessment of the Extent of Coronary Artery Disease Following Myocardial Infarction: Comparative Use of Exercise Radionuclide Ejection Fraction Response and Segmental Wall Motion”, Clin Res 30:19A, 1982.

6. Kimchi A, Rozanski A, Morris D, Frankel C, Harzman S, Franklin N, Maddahi J,

Swan HJC, Berman D. “Paradoxic Reversal of Resting Myocardial Wall Motion Abnormalities With Exercise”, Clin Res 30:197A, 1982.

DDB CV 18 of 29

7. Levey M, Ford D, Rozanski A, Maddahi J, Morris D, Pantaleo N, Kimchi A, Swan

HJC, Berman D. “Comparative Ability of Upright and Supine Bicycle Exercise to Detect Coronary Artery Disease”, Clin Res 30:200A, 1982.

8. Valovis R, Rozanski A, Levy R, Morris D, Ford D, Pantaleo N, Maddahi J, Swan

HJC, Berman D. “ECG Correlates of Severe Cardiovascular Dysfunction During Maximal Exercise Testing in Patients With Coronary Artery Disease”, Clin Res 30:95A, 1982.

9. Rozanski A, Maddahi J, Diamond G, Forrester J, Morris D, Garcia E, Swan HJC,

Berman D. “Are Patients With Normal Coronary Arteriograms Suitable for Establishing Normal Limits for Functional Non-Invasive Tests?”, J Nucl Med 23(5):82, 1982.

10. Morris D, Rozanski A, Berman D, Maddahi J, Kimchi A, Reisman S, Murphy F,

Swan HJC. “Accurate Detection of ‘High Risk’ Disease in Patients Post Myocardial Infarction by Exercise Radionuclide Ventriculography”, Circulation 66(4):ll-272, 1982.

11. Morris D, Rozanski A, Berman D, Swan HJC, Forrester J. “Accurate Scintigraphic

Assessment of the Location and Extent of Coronary Artery Disease in Patients With Prior Subendocardial Myocardial Infarction”, Clin Res 31:014A, 1983.

12. Morris D, Rozanski A, Diamond G, Becerra A, Berman D. “Comparative

Assessment of the Sub-Maximal and Maximal Exercise Ejection Fraction Response in the Diagnosis of Coronary Artery Disease”, Clin Res 31:014A, 1983.

13. Berchin J, Morris D, Rozanski A, Berman D. “The Safety of Post-Exercise Imaging

in the Upright Position Following Maximal Bicycle Stress: Experience in 2219 Patients”, Clin Res 31:004A, 1983.

14. Rozanski A, Diamond G, Berman D, Morris D, Forrester J, Swan HJC. “The

‘Normal’ Exercise Ejection Fraction Response in Better Defined in Relation to the Resting Value”, Clin Res 31:05, 1983.

15. Rozanski A, Diamond G, Berman D, Morris D, Pollock B, Swan HJC. “Can

Probability Analysis Predict the Ejection Fraction Response to Exercise?” Clin Res 31:01 7A, 1983.

16. Becerra A, Morris D, Maddahi J, Rozanski A, Waxman A, Berman D. “Comparative

Sensitivity of Thallium-201 Scintigraphy in Patients With and Without Myocardial Infarction”, Clin Res 31:014A, 1983.

17. Morris D and Lew W. “The Incidence of Complete Heart Block During Bedside

Pulmonary Artery Catheterization in Patients with Chronic Left Bundle Branch Block”, Clin Res 33:013A, 1985.

DDB CV 19 of 29

18. Engler RL, Schmid-Schoenbein GW, Dahlgren M, Morris D. “Leukocyte Depletion Prevents Edema Formation During One Hour of Myocardial Ischemia”, Fed Proc 44821, 1985.

19. Engler RL, Schmid-Schoenbein GW, Dahlgren M, Morris D. “Leukocyte Depletion

Prevents Ventricular Fibrillation During One Hour of Ischemia in the Dog”, Clin Res 33:182A, 1985.

20. Denise D Hermann, Johannes J Kuiper, Ralph Shabetai, Denise A Carethers,

David J Shaw, Barry H Greenberg. University of California at San Diego, San Diego, CA. “Herbal and Nutritional Supplement (Naturoceutical) Use in Heart Failure Patient Population”, J Cardiac Failure, Volume 4 Number 3 Supplement 1 Page 53:198, September 1998.

21. Hermann DD, Kuiper JJ, Shabetai R, Carethers D, Shaw DJ, Greenberg BH.

“Herbal, Megavitamin and Nutritional Supplement (Naturoceutical) Use is Very Common in Heart Failure Patient Populations”, JACC 33:Suppl 1199-3:201A, 1999.

22. Hanna RF, Barnard DD. “Women’s Awareness of Cardiovascular Disease Risk. A

University of California San Diego Regional Survey”, Circulation, Volume 111 Number 4 Page E-82, February 2005.

23. Barnard DD. “Heart Failure in Women”, Current Cardiology Reports, Volume 7

Number 3 Pages 159-165, May 2005. 24. Barnard DD. “Who Cares for the Patient with Heart Failure?” Current Cardiology

Reports, Volume 8, Number 3 Pages 163-170, August 2011.

E. NATIONAL AND INTERNATIONAL PRESENTATIONS

11/1982 “Accurate Detection of ‘High Risk’ Disease in Patients Post Myocardial Infarction by Exercise Radionuclide Ventriculography”, HA 55th Annual Scientific Sessions, Dallas, Texas

2/1983 “Accurate Scintigraphic Assessment of the Location and Extent of

Coronary Artery Disease in Patients With Prior Subendocardial Myocardial Infarction”, AFCR Western Regional Meetings, Carmel, CA.

2/1983 “The ‘Normal’ Exercise Ejection Fraction Response is Better Defined in

Relation to the Resting Value”, AFCR Western Regional Meetings, Carmel, CA.

5/1997 “Use of Carvedilol in Patients with Congestive Heart Failure--Practical

Experience”, SmithKline Beecham Pharmaceutical Representative Training Session.

10/1999 Cardiovascular Consultants of Nevada, 3rd Annual Symposium on

Cardiovascular Disease: “The Pros and Cons of Alternative Medicine Therapies”, Las Vegas, NV.

DDB CV 20 of 29

7/ 2000 Plenary Session Speaker, “Herbal, Megavitamin and Nutritional

Supplement (Naturoceutical) Consumption by Heart Failure Patients”, 7th World Congress on Heart Failure, Mechanisms and Management, Vancouver, BC, Canada

9/2000 “Heart Failure Diagnostic Algorithm Construction” Heart Failure Society of

America Guidelines and Clinical Positions Committee Update. Presentation to Society Membership. HFSA Annual Sessions, Boca Raton, FL

10/ 2000 Invited Lecture and Panelist: “Gender Differences in Cardiovascular

Disease; Natural History, Diagnosis and Management”, American Academy of Family Physicians, John Wilson Lectureship, Cardiology Update 2000. Albuquerque NM.

10/ 2000 Invited Lecture and Panelist, “Naturoceutical Agents and Cardiovascular

Medicines--The Hope, the Hype, the Harm: American Academy of Family Physicians, John Wilson Lectureship, Cardiology Update 2000. Albuquerque, NM.

11/2000 Abstract Presentation Session Co-Chair, American Heart Association

Annual Scientific Sessions, New Orleans LA

3/2001 Panelist, “Diastolic Heart Failure” American College of Cardiology 50th Annual Scientific Sessions, Orlando FL

3/2001 Program Moderator and Panelist, “Alternative Therapies for Heart Failure:

Nutraceuticals and LifeStyle Changes” American College of Cardiology 50th Annual Scientific Sessions, Orlando FL.

3/2001 Abstract Presentation Session Co-Chair, “Tachycardia-induced

Cardiomyopathies” American College of Cardiology 50th Annual Scientific Sessions, Orlando FL

9/2001 Program Moderator and Panelist, “How to Incorporate End-of-Life Issues

into Care?” Heart Failure Society of America 5th Annual Scientific Meeting, Washington, DC

9/2001 “Alternative and Complimentary Therapies: What Are Our Patients

Doing?” HFSA 5th Annual Scientific Meeting, Washington, DC

9/2001 Invited Lecturer, HFSA Special Session, HFSA Clinical Practice Guidelines Revisited: Strategies for the Next Guideline: “Role of General Measures for Heart Failure Practice Guideline”. Heart Failure Society of America 5th Annual Scientific Meeting, Washington, DC,.

9/2002 Sessions Moderator. “Managing Polypharmacy, Drug Interactions, and

Alternative Pharmacological Treatments” 6th Annual Scientific Sessions, Boca Raton, FL

DDB CV 21 of 29

9/2002 Invited Lecturer, HFSA 6th Annual Scientific Sessions: “Role of General Measures in Heart Failure Care” Boca Raton, FL.

4/2003 Co-Chair, ACC Session, Complex Patient and Lesion Management.

American College of Cardiology 52nd Annual Scientific Sessions, Chicago, IL

9/2003 Invited Lecturer, HFSA 7th Annual Scientific Sessions “Treating Cognitive

Impairment in Heart Failure”, Las Vegas, NV.

9/2004 Invited Lecturer, HFSA 8th Annual Scientific Sessions. Traditional "Salvage": Transplantation Still Too Little, Too Late? Toronto Ontario, Canada.

1/2005 Poster Presentation. 2nd International Conference on Women, Heart

Disease and Stroke, American Heart Association, Orlando, FL

F. INVITED LECTURES, LOCAL AND REGIONAL

6/1990 “Chest Pain? Get a PET!, An introduction to cardiac PET imaging and applications: Medical Grand Rounds, UCSD Medical Center. San Diego, CA.

6/1994 “Post-Transplant Immunosuppression: What every Cardiologist Should

Know”, Cardiology Grand Rounds, UCSD Medical Center, San Diego, CA. 11/1994 “Current Management of CHF”, UCSD Cardiology Core Curriculum Lecture

series for Primary Care Physicians, Thornton Hospital, San Diego, CA. 12/995 Plasma Ultrafiltration: “An Alternative to Inotrope Therapy for Chronic

Congestive Heart Failure?” Cardiology Grand Rounds, UCSD Medical Center, San Diego, CA

8/1995 “Chronic Heart Failure”--Evaluation and Management, VA Triage lecture

series, VA Medical Center, San Diego, CA. 11/1995 “Inotropic Therapy of End-Stage Heart Failure”, Joint UCSD-Brazilian

Society of Cardiology Symposium, Focus on the Pathogenesis, Prevention and Treatment of Heart Failure: A Pan-American Perspective, San Diego, CA.

6/1995 “Current Therapy of Heart Failure, From Dig to Dobutamine”, UCSD

Symposium--Heart Failure in 1995, New Paradigms and Prospects for a Common Syndrome, Office of Continuing Medical Education, La Jolla, CA.

9/1995 “Medical Management of Heart Failure”, UCSD Home Care Nursing

Continuing Education, San Diego, CA

DDB CV 22 of 29

2/1996 “Inotropes or Ultrafiltration in the Management of Refractory Heart Failure?” Grand Rounds Sharp Memorial Hospital, San Diego, CA

6/1996 “Exercise Testing in Heart Failure Patients -- When and Why”. Second

Annual Heart Failure Symposium, La Jolla, CA. 8/1996 “Heart Failure, an Overview”, UCSD Nursing Continuing Education Lecture

Series, UCSD Medical Center, San Diego, CA. 9/1996 In-Service Lecture, VA Medical Center Nursing Staff (MICU, Hemodialysis

Unit, SDTU staff) “Inotropes or Ultrafiltration in the Management of Refractory Heart Failure”, San Diego, CA.

10/1996 “Practical Medical Management of Heart Failure”, San Diego Outcomes

Group Seminar, San Diego, CA. 10/1996 “So, What is Heart Failure-Anyway?” UCSD Cardiomyopathy Patient and

Family Support Group, UCSD Medical Center, San Diego, CA. 2/1997 “Outpatient Management of Heart Failure-1997”, Mercy Medical Center,

Noon Conference Series, CME, San Diego, CA. 6/1997 Session Moderator, Discussant “How to Set up a Heart Failure Clinic”,

UCSD Heart Failure 1998 Symposium, La Jolla, CA. 6/1997 Panel Moderator and Invited Speaker, “Inotrope Treatment of Heart

Failure--Current Thoughts” UCSD Heart Failure 1997 Symposium, La Jolla, CA.

4/1997 “Outpatient Management of Heart Failure-1997”, UCSD Resident

Ambulatory Care Conference, San Diego, CA. 4/1997 “Management of Adult Congenital Heart Disease”, UCSD M&M

Conference, San Diego, CA. 6/1998 “Non-Ace Inhibitor Vasodilators- Nitrates, Calcium Blockers and

Angiotensin-II Receptor Blockers”, Fourth Annual Heart Failure Symposium, La Jolla, CA.

9/1998 Mercy Hospital Noon CME Lecture: “Heart Failure Management –

Contemporary Therapy”, San Diego, CA. 10/1998 UCSD Medicine Noon CME Lecture: “Heart Failure and Cardiac

Transplantation”, San Diego, CA. 10/1998 La Jolla VA Medical Center Noon CME Lecture: “Heart Failure and Cardiac

Transplantation”, San Diego, CA. 3/1999 Camp Pendleton CME Conference, “Heart Failure Therapy 1999 and

Beyond”, Oceanside, CA.

DDB CV 23 of 29

5/1999 UCSD Medical Center, M & M Conference: “Adult Congenital Heart

Disease”, San Diego, CA. 6/1999 Panel Moderator and Invited Speaker, “Naturoceutical Agents in Heart

Failure Patient Use and Implications”, 5th Annual UCSD Heart Failure Symposium, La Jolla, CA.

6/1999 Session Moderator, Discussant “How to Set up a Heart Failure Clinic”,

UCSD Heart Failure 1999 Symposium, La Jolla, CA. 8/1999 “CHF” and Treatment of the Failing Heart, UCSD Nursing Continuing

Education Lecture, San Diego, CA. 11/1999 UCSD Medical Center, M & M Conference: “Myocarditis”, San Diego, CA. 12/1999 UCSD Medical Center, Medicine Grand Rounds, “Naturoceutical Agents

and Heart Failure”, San Diego, CA. 2/2000 invited Speaker, “How to Prevent Heart Failure”, 1st Annual UCSD Heart

Failure Symposium for the Primary Care Physician, La Jolla, CA. 2/2000 Invited Speaker, “Nuts, Bolts and Screws of Diuretic Therapy (Including

Use of Spironolactone)” 1st Annual UCSD Heart Failure Symposium for the Primary Care Physician, La Jolla, CA.

2/2000 Invited Speaker, “Alternative Medicine in Cardiology: Risks and Benefits

of Naturoceuticals”, UCSD – 25th Annual Topics and Advances in Internal Medicine, La Jolla, CA.

3/2000 UCSD Medical Center, M & M Conference: “Heart Failure presenting as

Liver Failure”, San Diego, CA. 6/2000 Invited Speaker and Moderator, “Gender Differences in the Natural

History, Presentation and Therapy of Heart Failure”, 6th Annual UCSD Heart Failure Symposium: Heart Failure in the New Millennium, La Jolla, CA.

6/2000 Panel Moderator, “How To Set Up A Heart Failure Program”, 6th Annual

UCSD Heart Failure Symposium: Heart Failure in the New Millennium, La Jolla, CA.

6/2000 Panel Moderator, “New Approaches To Treating Heart Failure”, 6th Annual

UCSD Heart Failure Symposium: Heart Failure in the New Millennium, La Jolla, CA.

7/2000 Invited Speaker, “Management of Refractory Heart Failure”, Critical Care

Summer Sessions, UCSD School of Medicine, San Diego, CA.

DDB CV 24 of 29

9/2000 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant Recipients”, San Diego, CA.

9/2000 Heart Failure Task Force Recommendations and Guidelines, UCSD Medical

Center Staff Education CME Conference, San Diego, CA. 9/2000 Medicine Grand Rounds, “New Advances in the treatment of Chronic

Heart Failure”, Long Beach Memorial Medical Center, Long Beach, CA. 9/2000 Journal Club, Invited Professor, Long Beach Memorial Medical Center,

Long Beach, CA. 2/2001 Invited Speaker and Panel Moderator, “Heart Failure in the Elderly –

Diagnosis and Treatment”, 2nd Annual UCSD Heart Failure Symposium for Primary Care Physicians, San Diego, CA.

2/2001 Invited Speaker, “Gender Differences in the Natural History, Presentation

and Therapy of Heart Disease”, Office Gynecology and Women’s’ Health for the Primary Care Physician, Continuing Medical Association Associates. Coronado, CA.

5/2001 Invited Speaker and Panel Moderator, “Heart Failure Guidelines—How do

we Implement them into Clinical Practice?”, 7th Annual UCSD Heart Failure Symposium, La Jolla, CA.

9/2001 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA. 5/2001 Panelist and Moderator, “Management of Diastolic Heart Failure”, 7th

Annual UCSD Heart Failure Symposium: La Jolla, CA. 2/2002 Grand Rounds Alvarado Hospital. “ B-Type Natriuretic Peptide: A New

Approach to Acute Decompensated Heart Failure”. San Diego, CA. 2/2002 Panelist for Case Presentations, Heart Failure Society of America

Symposium, Heart Failure 2002: Update for the Primary Care Physician”. La Jolla, CA.

3/2002 Noon Cardiology Conference, Scripps Mercy. “Naturoceutical Agents and

Cardiovascular”. San Diego, CA. 4/2002 Invited Lecturer: Issues in Managing the Acutely Ill MedSurg Patient

Conference. “The MedSurg Patient with Acutely Decompensated Heart Failure”. San Diego, CA.

5/2002 Invited Speaker and Panel Moderator, “End of Life Management”, 8th

Annual UCSD Heart Failure Symposium, La Jolla, CA. 7/2002 CME Lecture Mercy Scripps. “ The Role of Beta Blockers in the High Risk

Heart Failure Patient”. San Diego, CA.

DDB CV 25 of 29

7/2002 Invited Lecturer UCSD Critical Care Conference: “ Cardiomyopathy:

Systolic vs Diastolic Failure”. San Diego, CA. 8/2002 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA. 11/2002 Cardiac Cath Conference at Sharp Medical Center. “Treatment Options of

Acute Decompensated Heart Failure”, Chula Vista, CA. 1/2003 Invited Lecturer Guidant Program at Doubletree: “ Women and Heart

Disease”. San Diego, CA. 1/2003 Invited Lecturer at UCI Medical Center Research Conference.

"Naturoceuticals and Other Complementary Therapies for Cardiovascular Risk Reduction and Treatment", Orange, CA.

2/2003 Invited Lecturer at 3rd Annual UCSD Heart Failure Symposium for Primary

Care Physicians. “Unusual and Unexpected Symptoms of Heart Failure” La Jolla, CA.

2/2003 Invited Lecturer at 3rd Annual UCSD Heart Failure Symposium for Primary

Care Physicians. “ An Approach to Treating End-Stage Heart Failure” La Jolla, CA.

2/2003 Panel Moderator at 3rd Annual UCSD Heart Failure Symposium for Primary

Care Physicians La Jolla, CA. 2/2003 Invited Lecturer at Scripps Mercy Cardiology Conference. “Naturoceuticals

and Heart Disease: What are YOUR patients taking?” San Diego, CA. 3/2003 UCSD Topics and Advances in Internal Medicine Conference. “Vitamin,

Herb/Uses, Misuses and Interactions with Conventional Medications” San Diego, CA.

3/2003 Invited Lecturer at Congregation Beth Israel. “Women and Heart

Disease”. Hadassah Healthy Women Healthy Lives Program, La Jolla, CA. 5/2003 Invited Lecturer at 9th Annual UCSD Heart Failure Symposium,

“Naturoceuticals and Other Alternative Therapies for Heart Failure”. La Jolla, CA.

5/2003 Panel Moderator at 9th Annual UCSD Heart Failure Symposium, La Jolla,

CA. 9/2003 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA.

DDB CV 26 of 29

5/2004 Invited Lecturer at 10th Annual UCSD Heart Failure Symposium, “Selection and Management of Patients for Cardiac Transplantation and Left Ventricular Assist Devices”. La Jolla, CA.

7/2004 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA. 7/2004 Invited Lecturer, University of San Diego (USD) Senior’s Extension

Course. “UCSD”s Cardiovascular Center Overview” San Diego, CA. 8/2004 Invited Lecturer, UCSD ICL Extension. “What IS Heart Failure anyways?”

San Diego, CA. 2/2005 Invited Lecturer at 5th Annual UCSD Heart Failure Symposium for Primary

Care Physicians, “Herbs, Nuts and Berries - Do Naturoceutical Drugs Have Any Role in the Treatment of Heart Failure?” La Jolla, CA.

2/2005 Panel Moderator at 5th Annual UCSD Heart Failure Symposium for Primary

Care Physicians, La Jolla, CA. 2/2005 Invited Lecturer, “Women and Cardiovascular Disease, What every

Woman should Know”. Rancho Santa Fe Chapter, National Charity League. Racho Sante Fe, CA.

3/2005 Panelist at 1st Annual UCSD Cardiovascular Center Symposium entitled

“Biomarkers in Heart Disease: What Every Health Care Practitioner Needs to Know”. La Jolla, CA.

4/2005 Invited Lecturer, Novartis Pharmaceuticals National Cardiovascular

Scientific Operations group. “Women and Cardiovascular Disease” Rancho Mirage, CA

6/2005 Invited Lecturer at 11th Annual UCSD Heart Failure Symposium, “Heart

Failure in Women, Patterns, Practices and Prognosis” La Jolla, CA. 4/2005 Invited Lecturer, Kaiser Permanente Cardiology Division. Devices &

Advanced Heart Failure, End of Life Decisions, Discussions and Dilemmas. San Diego, CA .

6/2005 Program Chair and Speaker, UCSD Cardiovascular Center Women’s

Cardiovascular Health Program, a Public Awareness Forum, San Diego, CA.

6/2005 Invited Lecturer, 11th Annual San Diego Heart Failure Symposium. “Heart

Failure in Women: Patterns, Practices and Prognosis” San Diego, CA. 6/2005 Invited Lecturer, American Heart Association, Mended Hearts Group.

“Women and Cardiovascular Disease” San Diego, CA.

DDB CV 27 of 29

2/2006 6th Annual UCSD Heart Failure Symposium for Primary Care Phyicians Moderator and Invited lecturer: “Managing Heart Failure in the Very Old Patient: A Common Problem in the Office Setting”. La Jolla, CA.

3/2006 UCSD Topics and Advances in Internal Medicine. Invited Lecturer:

“Naturoceutical Agents, Complementary and Alternative Medicine Practices in Cardiovascular Disease.” San Diego, CA.

5/2006 Invited Speaker American Heart Association Go Red For Women

“Hypertension in Women” La Jolla, CA. 7/2006 Invited Speaker Critical Care summer Session. “Cardiac Transplantation in

the ICU” La Jolla, CA. 6/2006 Invited Lecturer 12th Annual San Diego Heart Failure Symposium.

“Challenges in Managing Heart failure in Special populations: Women, the Elderly and Minorities” La Jolla, CA.

7/2006 Invited Speaker Critical Care summer Session. “Cardiac Transplantation in

the ICU” La Jolla, CA 7/2006 Invited Speaker UCSD “Health Matters” television show. Topic: women’s

cardiovascular health. 9/2006 Faculty Ambassador Lecture “Cardiovascular Disease in Women, an Equal

Opportunity Killer”

2/2007 AHA Go Red Program Speaker “What Every Woman Needs to Know about

Heart Disease”. 2/2007 Invited Lecturer 6th Annual UCSD Heart Failure for Primary Care

Physicians Symposium “Nuts, Bolts and Croutons of Heart Failure: How and When to Use Dig, Diuretics and Nitrates” San Diego, CA

2/2007 Las Damas Lecture, Fairbanks Ranch “What Every Woman Should know

About Heart Disease”.

3/2007 Scripps Mercy Noon Conference, “Women’s Cardiovascular Health and

Disease Focus on Hypertension”. 4/2007 SDSU/Preventative Medicine “Cardiovascular Disease in Women and

Equal Opportunity Killer”

5/2007 13th Annual Heart Failure Symposium, Advances in the Recognition

Treatment of Heart Failure, “Options for Patients with End-Stage Heart Failure” La Jolla, CA

9/2007 Invited Speaker “What is Heart Disease?” Bodies, The Exhibition. La Jolla,

CA.

DDB CV 28 of 29

10/2007 Guest Speaker “Women & Heart Disease; Focus on Hypertension” La Jolla, CA. (CME) Presenter on Women’s Health Program Sponsored by Internal Medicine News, OBGYN News and Family Practice News

10/2007 Invited Speaker, “Women & Cardiovascular Disease; California Chapter,

American College of Physicians Annual Meeting. 11/2007 Invited Speaker, Qualcomm Women Executives Group La Jolla, CA. 1/2008 8th Annual Heart Failure Symposium, for Internists and Primary Care

Physicians, “Expect the Unexpected-When to suspect That It Might Not Be a Routine Case of Heart Failure” La Jolla, CA.

5/2008 14th Annual Heart Failure Symposium, Advances in the Recognition and

Treatment of Heart Failure, “Anemia in the Heart Failure Patient: How to Work-up and When to Treat” La Jolla, CA.

6/2008 UCSD Cardiology Fellow’s Lecture 1/2008 2nd Annual Healthy Heart Expo, “Women and Heart Disease”, La Jolla,

CA 1/2008 8th Annual Heart Failure Symposium, for Internists and Primary Care

Physicians, “Expect the Unexpected-When to suspect That It Might Not Be a Routine Case of Heart Failure” La Jolla, CA.

5/2008 14th Annual Heart Failure Symposium, Advances in the Recognition and

Treatment of Heart Failure, “Anemia in the Heart Failure Patient: How to Work-up and When to Treat” La Jolla, CA.

6/2008 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA. 12/2008 Cardiology Fellow Core Lecture Series, “Management of Heart Transplant

Recipients”, San Diego, CA 1/2009 3rd Annual Healthy Heart Expo, “Women and Heart Disease”, La Jolla,

CA. 1/2009 9th Annual Heart Failure Symposium, for Internists and Primary Care

Physicians, “Risk and Treatment of Anemia in Heart Failure” 3/2009 UCSD Health and Wellness Lecture Series, “Heartburn or Heart Attack?

Diagnosis of Cardiovascular Disease in Women”, La Jolla, CA 6/2009 15th Annual San Diego Heart Failure and Hypertension Symposium, “Risk

and Treatment of Anemia in Heart Failure”, La Jolla, CA 8/2009 Grand Rounds Present “Heart Disease in Women” Liebow Auditorium, La Jolla, CA 10/2009 1st Annual State of the Art Cardiovascular Medicine Conference Lecture “Management of End Stage Heart Failure” San Diego, CA.

DDB CV 29 of 29

1/2010 “Presentation on Cardiovascular Disease in Women” Scripps Mercy

Hospital, San Diego, CA 1/2010 10th Annual UCSD Heart Failure & Hypertension Symposium “Managing Co-Morbidities Including Angina, Anemia and Sleep Apnea In

Hypertensive and Heart Failure Patients” La Jolla, CA 5/2010 16th Annual San Diego Heart Failure & Hypertension Symposium “Treatment of Hyponatremia and Anemia in the Heart Failure Patient” La Jolla, CA 7/2011 “Appropriate Use Criteria for Diagnostic Catheterization Technical Panel” Hilton O’Hare, Chicago, IL. 8/2011 “Acute Decompensated heart Failure” Trout Room, UCSD La Jolla, CA 9/2011 “15 annual Scientific meeting of the HFSA Session Clinical

Fundamentals: Atrial and Ventricular Arrhythmias/Troubleshooting CRT/ICD/Mechanical Circulatory Support”. Hynes convention Center in Boston, MA.